Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | UQCRB | P14927 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087092 | 0.82 | CA1 (0.50) | CA1CA2LMNAHTT | |
| SCHEMBL6086434 | 0.80 | CA1 (0.63) | CA1CA2PKMALDH1A1KMT2A | |
| SCHEMBL6088704 | 0.80 | CA1 (0.49) | CA1CA2ALDH1A1LMNAHTT | |
| SCHEMBL6087498 | 0.79 | CA1 (0.64) | CA1CA2UQCRBALDH1A1LMNA | |
| SCHEMBL7175051 | 0.79 | HSD17B2 (0.72) | HSD17B2PKMUQCRBALDH1A1HSD17B1 | |
| SCHEMBL6073362 | 0.78 | CA1 (0.62) | CA1CA2PKMALDH1A1KMT2A | |
| SCHEMBL6087365 | 0.78 | CA1 (0.58) | CA1CA2HSD17B2LMNAHTT | |
| SCHEMBL7159686 | 0.78 | CA1 (0.60) | CA1CA2PKMALDH1A1LMNA | |
| SCHEMBL7171908 | 0.78 | PKM (0.62) | HSD17B2PKMUQCRBALDH1A1LMNA | |
| SCHEMBL16720181 | 0.77 | HSD17B2 (0.71) | HSD17B2PKMUQCRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2003-08-28 | — | — | US | claimed |
| JP-3421350-B2 | — | — | 2003-06-30 | — | — | JP | claimed |
| US-6482860-B1 | such as batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene), use as antiproliferative agents to treat cancer | TULARIK INC. | 2002-11-19 | — | — | US | claimed |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2002-10-03 | — | — | US | claimed |
| JP-2000515545-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0939627-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0939627-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-09-08 | — | — | EP | claimed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | claimed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | claimed |
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-6962929-B2 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-0896533-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1090014-B1 | ARYLSULFONANILIDE PHOSPHATES | TULARIK INC (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-0896533-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | disclosed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | disclosed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | FGFR1, FPR1, FGF1 | CA1 3297/4885CA2 3367/4885HSD17B2 2754/4885 |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | FFAR1, PCSK9, PFAS | CA1 2017/4885CA2 3421/4885HSD17B2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.